CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
OPERATING ACTIVITIES
Net loss	$ (3,522)	$ (1,256)
Adjustments to reconcile net loss to net cash used in operating activities:
Forgiveness of notes payable		(408)
Share-based compensation expense	512	261
Depreciation	27	66
Change in fair value of warrant liability	(2)	(12)
Changes in operating assets and liabilities:
Grant receivable		7
Prepaid expenses and other current assets	198	261
Other assets	(173)
Accounts payable	823	8
Accrued and other current liabilities	483	(100)
Net cash used in operating activities	(1,654)	(1,173)
INVESTING ACTIVITIES
Purchases of property, plant, and equipment	(8)
Net cash used in investing activities	(8)
FINANCING ACTIVITIES
Proceeds from issuance of common stock and warrants	5,060	598
Net cash provided by financing activities	5,060	598
Net increase (decrease) in cash and restricted cash	3,398	(575)
Cash and restricted cash at the beginning of the year	1,292	1,076
Cash and restricted cash at the end of the period	4,690	$ 501
Supplemental disclosure of non-cash activities:
Settlement of contingency matter	(3,250)
Settlement of due to Harvard Bioscience included in accrued and other current liabilities	(750)
Issuance of Series E convertible preferred stock	4,000
Preferred stock dividends	$ 18